NANOVIRICIDES, INC. NNVC
On September 25, 2013, the Company's common stock began trading on the New York Stock Exchange American under the symbol, "NNVC".
We are a clinical stage company with our first drug ready to enter Phase II human clinical efficacy trial, having successfully completed Phase Ia/Ib human clinical safety and tolerability trial. Based on our nanoviricides™ platform technology, we also have several additional drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations.
We are engaged in developing a class of drugs, that we call nanoviricides™, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. This approach enables rapid development of effective new drugs against a number of different viruses, that the viruses are highly unlikely to escape even as they evolve rapidly in the field, solving an important problem in attacking viruses. The virus evolution is known to generate viruses that escape the traditional antiviral approaches vaccines, antibodies and small chemical drugs.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — | — | — | — | — |
| R&D | $5.5M | $5.4M | $6.4M | $5.8M | $6.1M | $4.7M | $5.9M | $5.9M | $6.6M | $5.0M |
| SG&A | $4.0M | $3.1M | $2.6M | $2.3M | $2.6M | $3.3M | $2.7M | $3.4M | $3.0M | $3.8M |
| Total operating expenses | $9.6M | $8.5M | $8.9M | $8.1M | $8.7M | $8.0M | $8.7M | $9.3M | $9.6M | $8.9M |
| Operating income | -$9.6M | -$8.5M | -$8.9M | -$8.1M | -$8.7M | -$8.0M | -$8.7M | -$9.3M | -$9.6M | -$8.9M |
| Interest expense | $149 | $49.8K | $938 | $5.1K | $85.4K | $93.7K | $0 | $185.3K | $780.8K | $1.0M |
| Pre-tax income | — | — | — | -$8.1M | -$8.8M | -$13.4M | -$8.4M | -$8.6M | -$10.3M | -$10.7M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9.5M | -$8.3M | -$8.6M | -$8.1M | -$8.8M | -$13.4M | -$8.4M | -$8.6M | -$10.3M | -$10.7M |
| EPS, basic | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | — | — | -0.13 | -0.17 | -0.19 |
| EPS, diluted | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -2.39 | -2.35 | -2.64 | -0.17 | -0.19 |
| Shares, diluted (wtd. avg.) | 15.1M | 11.9M | 11.6M | 11.5M | 10.9M | — | — | 64.9M | 60.1M | 57.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M | $13.7M | $2.6M | $7.1M | $15.1M | $24.2M |
| Total current assets | $1.7M | $5.0M | $8.4M | $14.4M | $20.8M | $14.0M | $2.8M | $7.3M | $15.3M | $24.4M |
| Property, plant and equipment | $6.8M | $7.5M | $8.1M | $8.7M | $9.1M | $9.5M | $10.2M | $10.8M | $11.3M | $11.8M |
| Other intangibles | $317.0K | $325.3K | $333.6K | $341.8K | $350.1K | $358.4K | $366.7K | $374.9K | $383.2K | $391.5K |
| Total assets | $8.8M | $12.8M | $16.9M | $23.5M | $30.3M | $23.9M | $13.4M | $18.5M | $27.0M | $36.6M |
| Short-term debt | — | — | — | — | — | — | — | — | — | $5.5M |
| Total current liabilities | $1.3M | $1.4M | $534.2K | $412.8K | $351.1K | $2.2M | $2.8M | $881.9K | $4.7M | $6.7M |
| Long-term debt | — | — | — | — | — | — | — | — | $4.7M | — |
| Total liabilities | $1.3M | $1.4M | $2.0M | $412.8K | — | — | — | $881.9K | $6.7M | $13.6M |
| Retained earnings | -$148.8M | -$139.4M | -$131.1M | -$122.5M | -$114.4M | -$105.6M | -$92.1M | -$83.7M | -$75.1M | -$64.8M |
| Total equity | $7.5M | $11.5M | $14.9M | $23.1M | $29.9M | $21.8M | $10.6M | $17.7M | $20.3M | $23.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.5M | -$6.3M | -$5.7M | -$5.9M | -$8.2M | -$6.7M | -$6.8M | -$7.8M | -$7.9M | -$6.8M |
| Depreciation and amortisation | $735.5K | $750.7K | $739.3K | $715.1K | $696.3K | $691.5K | $687.6K | $671.8K | $654.7K | $651.3K |
| Stock-based compensation | — | — | — | — | — | — | $35.8K | $156.2K | — | $158.0K |
| Capital expenditure | $57.0K | $156.6K | $151.7K | $324.3K | $238.8K | $8.6K | $73.8K | $241.8K | $165.0K | $476.4K |
| Investing cash flow | -$57.0K | -$156.6K | -$151.7K | -$324.3K | — | — | — | — | -$165.0K | -$476.4K |
| Financing cash flow | $5.3M | $3.1M | -$94.8K | -$234.7K | $15.3M | $17.8M | $2.4M | $0 | -$1.0M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-25-094527.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$10.7M | -$10.3M | -$8.6M | -$8.4M | -$13.4M | -$8.8M | -$8.1M | -$8.6M | -$8.3M | -$9.5M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |